Pharming Group N.V. (PHAR)
$9.79+2.73%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $691M
- Beta
- 0.09
- P/E (TTM)
- 66.38
- Short % float
- 0.03%
- Days to cover
- 1.0
- SI change
- -3.8%
- 1W
- +0.41%
- 1M
- -9.44%
- vs SPY 1W
- -0.75%
- vs SPY 1M
- -12.43%
Industry peers
FMP comparable companies · ranked by market cap
- BMRNSELLBioMarin Pharmaceutical Inc.$10.6BBEARQ 12$54.89-0.16%
- IONSSELLIonis Pharmaceuticals, Inc.$7.2BRECOVERYQ 8$43.30+4.57%
- PHVSSELLPharvaris N.V.$2.2BCRISISQ 15$31.12-0.06%
- BCRXSELLBioCryst Pharmaceuticals, Inc.$2.1BRECOVERYQ 6$8.29+3.14%
- NTLABUYIntellia Therapeutics, Inc.$1.8BRECOVERYQ 4$12.60+3.73%
- STOKSELLStoke Therapeutics, Inc.$1.5BCRISISQ 11$23.95+3.30%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PHAR?
- LOPJLB’s latest quantitative signal on Pharming Group N.V. (PHAR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PHAR in?
- Pharming Group N.V. (PHAR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Pharming Group N.V. (PHAR) do?
- Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esteras…